Omalizumab improves quality of life, angioedema in refractory urticaria patients

WASHINGTON – Treatment with omalizumab improved quality-of-life scores and had a significant impact on angioedema episodes in a phase IIIb study of people with treatment-refractory chronic idiopathic/spontaneous urticaria. In the double-blind <a...
Source: Skin and Allergy News - Category: Dermatology Source Type: news